At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PTPI Petros Pharmaceuticals Inc
Closed 04-26 16:00:00 EDT
0.6399
+0.0000
0.00%
盘后0.6350
-0.0049-0.77%
19:34 EDT
High0.6600
Low0.6350
Vol77.24K
Open0.6400
D1 Closing0.6399
Amplitude3.91%
Mkt Cap4.40M
Tradable Cap3.97M
Total Shares6.88M
T/O49.38K
T/O Rate1.25%
Tradable Shares6.20M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.